反应：依库珠单抗治疗后的母体和脐带C5a - Suppr

Response: Maternal and cord C5a in response to eculizumab.

作者信息

Burwick Richard M, Burwick Nicholas, Feinberg Bruce B

机构信息

Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

出版信息

Blood. 2015 Jul 9;126(2):279-80. doi: 10.1182/blood-2015-06-642553.

DOI:10.1182/blood-2015-06-642553

PMID:26160189

Abstract

摘要

相似文献

Response: Maternal and cord C5a in response to eculizumab.

Blood. 2015 Jul 9;126(2):279-80. doi: 10.1182/blood-2015-06-642553.

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.

Blood. 2015 Jul 9;126(2):278-9. doi: 10.1182/blood-2015-03-637645.

Eculizumab fails to inhibit generation of C5a in vivo.

Blood. 2014 Nov 27;124(23):3502-3. doi: 10.1182/blood-2014-07-589366.

Eculizumab for the treatment of preeclampsia/HELLP syndrome.

Placenta. 2013 Feb;34(2):201-3. doi: 10.1016/j.placenta.2012.11.014. Epub 2012 Dec 8.

Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.

Mol Immunol. 2017 Sep;89:111-114. doi: 10.1016/j.molimm.2017.05.021. Epub 2017 Jun 10.

Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.

Clin Immunol. 2017 Jul;180:25-32. doi: 10.1016/j.clim.2017.03.012. Epub 2017 Mar 30.

[HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review].

G Ital Nefrol. 2019 Apr;36(2).

Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report.

BMC Nephrol. 2019 Aug 7;20(1):307. doi: 10.1186/s12882-019-1469-9.

New concepts on the therapeutic control of complement anaphylatoxin receptors.

Mol Immunol. 2017 Sep;89:36-43. doi: 10.1016/j.molimm.2017.05.015. Epub 2017 May 30.

Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.

Clin Immunol. 2017 Oct;183:1-7. doi: 10.1016/j.clim.2017.06.007. Epub 2017 Jun 21.

引用本文的文献

The role of complement in normal pregnancy and preeclampsia.

Front Immunol. 2025 Jul 24;16:1643896. doi: 10.3389/fimmu.2025.1643896. eCollection 2025.

A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.

Kidney Int. 2024 May;105(5):960-970. doi: 10.1016/j.kint.2023.12.021. Epub 2024 Feb 24.

The Complement System and Preeclampsia.

Curr Hypertens Rep. 2017 Oct 18;19(11):87. doi: 10.1007/s11906-017-0784-4.

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Clin Exp Immunol. 2017 Feb;187(2):304-315. doi: 10.1111/cei.12890. Epub 2016 Nov 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Response: Maternal and cord C5a in response to eculizumab.

作者信息

Burwick Richard M, Burwick Nicholas, Feinberg Bruce B

机构信息

Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.

出版信息

Blood. 2015 Jul 9;126(2):279-80. doi: 10.1182/blood-2015-06-642553.

DOI:10.1182/blood-2015-06-642553

PMID:26160189

Abstract

摘要

相似文献

Response: Maternal and cord C5a in response to eculizumab.

Blood. 2015 Jul 9;126(2):279-80. doi: 10.1182/blood-2015-06-642553.

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.

Blood. 2015 Jul 9;126(2):278-9. doi: 10.1182/blood-2015-03-637645.

Eculizumab fails to inhibit generation of C5a in vivo.

Blood. 2014 Nov 27;124(23):3502-3. doi: 10.1182/blood-2014-07-589366.

Eculizumab for the treatment of preeclampsia/HELLP syndrome.

Placenta. 2013 Feb;34(2):201-3. doi: 10.1016/j.placenta.2012.11.014. Epub 2012 Dec 8.

Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.

Mol Immunol. 2017 Sep;89:111-114. doi: 10.1016/j.molimm.2017.05.021. Epub 2017 Jun 10.

Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.

Clin Immunol. 2017 Jul;180:25-32. doi: 10.1016/j.clim.2017.03.012. Epub 2017 Mar 30.

[HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review].

G Ital Nefrol. 2019 Apr;36(2).

Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report.

BMC Nephrol. 2019 Aug 7;20(1):307. doi: 10.1186/s12882-019-1469-9.

New concepts on the therapeutic control of complement anaphylatoxin receptors.

Mol Immunol. 2017 Sep;89:36-43. doi: 10.1016/j.molimm.2017.05.015. Epub 2017 May 30.

Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.

Clin Immunol. 2017 Oct;183:1-7. doi: 10.1016/j.clim.2017.06.007. Epub 2017 Jun 21.

引用本文的文献

The role of complement in normal pregnancy and preeclampsia.

Front Immunol. 2025 Jul 24;16:1643896. doi: 10.3389/fimmu.2025.1643896. eCollection 2025.

A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.

Kidney Int. 2024 May;105(5):960-970. doi: 10.1016/j.kint.2023.12.021. Epub 2024 Feb 24.

The Complement System and Preeclampsia.

Curr Hypertens Rep. 2017 Oct 18;19(11):87. doi: 10.1007/s11906-017-0784-4.

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Clin Exp Immunol. 2017 Feb;187(2):304-315. doi: 10.1111/cei.12890. Epub 2016 Nov 25.

Response: Maternal and cord C5a in response to eculizumab.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Response: Maternal and cord C5a in response to eculizumab.

作者信息

机构信息

出版信息

相似文献

引用本文的文献